[March 11, 2013]

Research and Markets: PharmaPoint: HIV - Spain Drug Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/tz2swd/pharmapoint_hiv) has announced the addition of GlobalData's new report "PharmaPoint: HIV - Spain Drug Forecast and Market Analysis to 2022" to their offering.

Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physiciansand patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

This highly competitive market comprises over 18 different drugs, many of which already exist as generics. Atripla was the first single-tablet regimen (STR) to enter Spain in 2007, ushering in an era of STR development and commercialization. ViiV Healthcare and Gilead Sciences are the main companies pursuing STRs in order to position themselves as the market leaders in Spain.

Scope

- Overview of Spain including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in Spain from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting Spain HIV market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for HIV

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2012-2022 in Spain

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Market Outlook

9 Appendix

For more information visit http://www.researchandmarkets.com/research/tz2swd/pharmapoint_hiv

Source (News - Alert): GlobalData

[ Back To Technology News's Homepage ]